Full Press Release Details
IDEAYA Announces Dose Expansion in Phase 1 2 Study of IDE196 and Binimetinib Combination in Metastatic Uveal Melanoma Based on Early Clinical Activity.
IDYA
IDEAYA Announces Dose Expansion in Phase 1 2 Study of IDE196 and Binimetinib Combination in Metastatic Uveal Melanoma Based on Early Clinical Activity
Key Takeaway: IDEAYA Announces Dose Expansion in Phase 1 2 Study of IDE196 and Binimetinib Combination in Metastatic Uveal Melanoma Based on Early Clinical Activity